Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression by Coventry, B J et al.
Dendritic cell density and activation status in human breast cancer
– CD1a, CMRF-44, CMRF-56 and CD-83 expression
BJ Coventry*
,1, P-L Lee
1, D Gibbs
2 and DNJ Hart
3
1Department of Surgery, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia;
2Haematology/Immunology
Research Group, University of Otago, Canterbury Health Laboratories, PO Box 151, Christchurch, New Zealand;
3Mater Medical Research Institute,
Mater Hospital, Brisbane, Queensland 4101, Australia
Low CD1a-positive putative dendritic cell numbers in human breast cancer has recently been described and may explain the
apparent ‘poor immunogenicity’ previously reported in breast cancer. Little attention has been given to dendritic cell activation
within the tumour microenvironment, which is another reason why the in-situ immune response may be severely deﬁcient.
We have therefore examined CD1a expression as a marker for dendritic cells, together with CMRF-44 and -56 as markers of
dendritic cell activation status, in 40 human breast cancers. The results demonstrate few or no CD1a-positive putative
dendritic cells and minimal or no expression of the dendritic cell activation markers. Both dendritic cell number and dendritic
cell activation appear substantially deﬁcient in human breast cancers, regardless of tumour histological grade.
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Breast adenocarcinoma has traditionally been thought of as a ‘non-
immunogenic’ tumour, despite numerous observations concerning
the notable density of the T-cell inﬁltrate in human and animal
breast cancers (Zhang et al, 1998). However, speciﬁc anti-tumour
responses by autologous T-lymphocytes inﬁltrating human breast
tumours have been documented using short-term cultured breast
carcinoma cells in-vitro (Baxevanis et al, 1994), and more wide-
spread interest in the possibility of generating immuno-
therapeutic responses against breast cancer has developed. Dendri-
tic cells (DC) have been identiﬁed as the specialist leukocyte
population capable of initiating and directing immune responses.
Studies of gastric, thyroid, lung and colorectal carcinomas have
shown that the density of putative dendritic cells (DC) (CD1a;
S-100 positive) is a predictor of survival (Tsujitani et al, 1987,
1988, 1990, 1992; Ambe et al, 1989; Schroder et al, 1988; Zeid
and Muller, 1993). Equally, more recent studies suggest minimal
recruitment and activation of DC in renal, prostate and bladder
cancers (Troy et al, 1998a,b, 1999) and that S-100 staining may
correlate with an activated DC subset (Troy et al, 1998a). More-
over, it has been shown that there is an inverse correlation
between tumour differentiation grade and the DC inﬁltrate for
some tumour types (Becker, 1992). Recent studies have demon-
strated a low number of CD1a positive cells in human breast
carcinomas (Hillenbrand et al, 1999) and these have been able to
be extracted using speciﬁc dissaggregation techniques (Coventry
et al, 1997). CD1a molecules appear to be expressed on epithelial
associated DC during the antigen capture and processing phase,
reducing in density as the DC phenotype develops full capacity
for antigen presentation in-vivo. The possibility that the ‘non-
immunogenicity’ of breast cancers may, in part, be due to low
DC inﬁltration, loss of DC from the tumour microenvironment
or lack of DC activation, requires further investigation.
DC are derived from bone marrow precursors and recent data
suggests that there are epithelial and non-epithelial associated
subsets, distinguishable on the basis of CD1a expression. Surveil-
lance DC require deﬁned ‘danger’ signals derived from microbial
organisms triggered by the innate immune response (perhaps lack-
ing in some cancers) to initiate antigen uptake, migration and
differentiation/ activation of DC co-stimulatory activity. Further
control of DC co-stimulatory activity occurs as a result of the DC/
T-cell interaction (Hart, 1997). Acquisition of CD86 is an important
end point of DC differentiation, signifying full co-stimulatory capa-
city (Thomas and Lipsky, 1996; Hart, 1997; McLellan et al, 1999).
Recent evidence suggests other mechanisms may downregulate DC
activation, depending on DC maturity (McLellan et al, 2000)
Effective antigen presentation within the tumour microenviron-
ment for speciﬁc anti-tumour immune responses might be
associated with differentiated, activated DCs. Equally it is possible
that tumours may fail to recruit DC or activate DC thereby evading
an effective anti-tumour response. CMRF-44 monoclonal antibody
(mAb) acts as a marker of allostimulatory activity in cultured
peripheral blood mononuclear cells (Hock et al, 1994; Vuckovic
et al, 1998), and deﬁnes an early differentiation activation marker
on DC present on only a small number of peripheral tissue DC.
Likewise the mAb CMRF-56 reacts with another early activation
antigen expressed in high density on DCs, but not with other rest-
ing or activated leukocytes (Hock et al, 1999). Both of these
markers show a strong correlation with a third DC differentiation/
activation antigen CD83 (Zhou and Tedder, 1995) as well as the
up-regulation of cells and other cytoplasmic markers. Interleukin
10 (IL10) expression as a potential inhibitor of T-cells and DC is
considered and discussed.
This study investigates the expression of the epithelial DC
marker CD1a with that of CMRF-44, CMRF-56 and CD83 to
determine the activation state of DC in human breast cancer.
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The studies were performed in two collaborating laboratories and
are reported in two parts – Part I (Adelaide) and Part II
(Christchurch). The studies were approved by and met the ethical
standards of both institutions.
Tissues and processing
Part I Fresh tissue was frozen in liquid nitrogen from samples
taken at routine surgery from 30 inﬁltrating ductal breast carcinomas
(IDC) (IDC grade I =10, IDC grade II =10, IDC grade III =10), then
stored at 7808C for later use. Samples were cut from intratumoural
portions of tumours that were palpable (rather than mammographi-
cally detected). Four to ﬁve mm serial sections (Leica Cryostat) were
mounted on gelatinized slides, left overnight, ﬁxed in cold (48C) acet-
one for 10 min and air dried for a minimum of 2 h.
All sections were pre-blocked with 10% goat or normal horse
serum in phosphate-buffered saline (PBS) for 20 min.
Part II Ten cases of breast cancer were obtained, frozen in liquid
nitrogen and processed similarly.
Immunohistochemical techniques
Monoclonal antibodies Part I Mouse monoclonal anti-human
antibodies, diluted in 10% normal horse serum (NHS), were used
at the following concentrations, CD1a at 1/500 (Dako, Denmark),
CMRF 44 and CMRF 56 both at 1/50 (D Hart, New Zealand),
mouse isotype negative control 2 mgm l
71 (Zymed, CA, USA).
The anti-interleukin 10 antibody 12G8 (IgG; Schering, NJ, USA)
was used at 1/500 dilution in separate studies brieﬂy mentioned
here. Biotinylated rabbit anti-mouse IgG/IgM second antibody at
1/500 (Dako, Denmark), and streptavidin-HRP at 1/1000 (Pierce,
USA). Single-staining protocol reactions were carried out at room
temperature. PBS 63 rinses were used after each staining step.
Following blocking with 10% NHS, sections were incubated for
1 h with the primary antibody, (CD1a for 1 h, or CMRF 44/56
overnight).
Part II The anti-CD3 (OKT3, IgG2a), antibody was produced
from a hybridoma obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). The antibodies CMRF-
12 (CD45, IgG1), CMRF-15 (negative control, IgM), CMRF-31
(CD14, IgG2a), CMRF-56 (activation antigen, IgG1) and CMRF-
44 (activation antigen, IgM) were produced and characterized in
this (DNJH) laboratory. The anti-CD83 mAb was purchased from
Immunotech. The anti CD16 mAb (HuNK-2, IgG2a) was a gift
from Professor IFC McKenzie (Melbourne, Australia). The CD1a
mAb (Na1/34, IgG2a), was a gift from Dr A McMichael (UK).
The negative control mAb Sal5 (IgG2a) and X63 (IgG1), were gifts
from Professor H Zola (Adelaide, Australia). Phycoerythrin-conju-
gated anti-CD45 and HLA-DR were purchased from Becton
Dickinson (Australia). PE-conjugated anti-CD83 was purchased
from Immunotech.
Immunoperoxidase labelling
Part I Biotinylated secondary antibody for 1 h. Endogenous
peroxide blocking (PBS and 0.5% H2O2 for 20 min) was followed
by a 1 h incubation in SHRP. Sections were reacted with nickel
chloride enhanced diaminobenzidene (DAB), and counterstained
with methyl green (Coventry et al, 1994, 1995) for higher detection
sensitivity. Lymph node sections from melanoma were used as
positive controls.
Part II Specimens were cut, ﬁxed and blocked as above. After
incubation with the primary antibody, slides were washed three
times in PBS and peroxidase-conjugated goat anti-mouse antibody
(PGAM) (DAKO) applied. The slides were washed in tris buffered
saline (TBS) then DAB applied. The reaction was terminated after
10–15 min by washing in PBS. Slides were counterstained, ﬁxed
and mounted as above.
Immunoﬂuorescence labelling
Part II only Specimens were cut, ﬁxed and blocked as above.
The primary antibody mix was applied for 30 min at room
temperature, then the slides were washed three times in PBS.
Fluorescein isothyanate-conjugated sheep anti-mouse antibody
(Silenus) was applied for 30 min. After washing three times in
PBS, the slides were blocked with 10% mouse serum for 10 min.
A Phycoerythrin-conjugated secondary antibody was applied for
30 min. After washing three times in PBS, the slides were mounted
in glycerol-gelatin with DABCO as an anti-fade agent. Slides were
stored in darkness at 7208C and examined within 24 h of prepara-
tion.
Characterization of cellular inﬁltrate
Part I CD1a, CMRF 44 and 56 density assessment was
performed by counting 50 random ﬁelds per frozen section, or
as many ﬁelds as possible if the section was smaller. The mean
of each section represented the density of the inﬁltrate (ﬁeld size
0.375 mm diameter; 0.44 mm
72; 4006 magniﬁcation). This
allowed estimation of the density and distribution of different cell
types in the inﬁltrate compared with CD1a
+ staining to be
expressed as cells per mm
72 (i.e. as in Part II).
Part II DC were identiﬁed in single label immunohistological
studies by size, morphology and staining with the appropriate
marker. The cells were counted in at least 10 medium power ﬁelds
using a calibrated graticule, then the number of cells per mm
72
was calculated. DC were identiﬁed in double label immunoﬂuores-
cence studies as CD45
+ (i.e. Phycoerythrin labelled) cells that were
negative (i.e. FITC negative) for the lineage markers CD3, CD14,
CD16 and CD19.
RESULTS
Identiﬁcation of putative dendritic cells
Part I CD1a
+ cells were present in 50% of the breast tissue
samples (n=30). The density of the inﬁltrate was variable
between samples (range 0.00–6.05/HPF; 0.00–13.75 mm
72;
mean=2.49 cells mm
72).
There was no association between density of CD1a
+ cells and
tumour grade (Kruskal-Wallis, P40.05).
DC occurred in small numbers relative to the number of CD3
+
cells. CD1a
+ cells, probably epithelial DC, were present in the great-
est numbers, as previously reported (Hillenbrand et al, 1999). The
CD1a
+ cells tended to occur in loose clusters (distinct from
lymphoid aggregates), so obtaining a count that accurately reﬂected
their numbers was difﬁcult. In some instances CD1a staining was
thought to be present on a sub-population of macrophages.
Faint CMRF-44
+ staining was observed in only one of the 30
breast carcinoma sections examined in this study (Figure 1), with
the same sample demonstrating relatively strong CMRF-56
+ immu-
nostaining (Figure 2), with CD1a
+ cells found clustered around a
tumour island (Figure 3). CD1a, CMRF-44 and -56 staining in
normal breast tissues was sparse or absent.
Part II The immunoenzymatic staining identiﬁed a similar
number of CD1a
+ DC in the second study (n=10), with a similar
range (0–16.6 mm
72). The mean number of CD1a
+ cells was
5.5 mm
72 and CD3 T-lymphocytes was 114.5 mm
72. Again
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 546–551limited staining with the activation markers was noted (CMRF 44
4CD83 4CMRF-56). There was a trend for the activated DC to
be associated with increased T-lymphocyte numbers (see below).
The double label immunoﬂuorescence studies identiﬁed very simi-
lar numbers of Lin
7/CD45
+ DC, most of which were CD1a
+, but
increased CD1a staining on macrophages was evident in some
cases. Counts were hampered by high non-speciﬁc background
staining as a consequence of auto-ﬂuorescence. Nonetheless, the
CD1a counts obtained by this method were comparable with
those obtained by immunohistochemistry. Comparing the line-
age-negative cell counts and the CD1a
+ cell counts suggests that
a subset of DC in breast cancers express the epithelial DC marker
CD1a (Table 1).
Identiﬁcation of activated dendritic cells
Although only one of 30 specimens was positive for CMRF-44 in
Part I using DAB enhanced immunoenzymatic methods, limited
numbers of CD83 and CMRF-44
+ cells were identiﬁed in most
specimens, using the alternative immunoenzymatic method or
ﬂuorescence method (Part II). CMRF-56
+ cells were only identiﬁed
in one specimen (for both Parts I and II; n=40) although other
specimens had peri-tumoural lymphoid aggregates which contained
cells that stained weakly with CMRF-56 (Table 1).
An attempt was made to assess co-expression of CD1a and
CD83 using immunoﬂuorescence techniques but high background
ﬂuorescence made identiﬁcation of phycoerythrin-labelled CD83
+
cells difﬁcult. However, since no CD1a
+/CD83
+ cells were identi-
ﬁed (as few CD83
+ cells could be identiﬁed by indirect
immunoﬂuorescence) the conclusion that the two markers identify
different populations of cells could not be established with
certainty. Nonetheless, the immunoﬂuorescence data conﬁrmed
the low number of CD83
+ cells present.
Location of CD1a
+ cells The CD1a
+ cells were present in the
stroma between islands of tumour cells and in more differentiated
tumours were situated around the ductal formations.
Interleukin 10 in human breast cancer In a separate study
IL10 expression was detected in 40 of 52 breast cancer specimens
examined using immunohistochemical methods. The histological
grade of the tumour did not correlate with the IL10 expression,
nor did CD3 or CD68 expression. The IL10 staining intensity
was low in all tumours and these cells were within the stroma
around the ducts in well to moderately differentiated tissues
(Neville, 1994).
DISCUSSION
The ﬁnding of paucity of CD1a
+ cells in many of the breast carci-
nomas examined indicated that DC mediated co-stimulation of T-
lymphocytes in many breast cancers is likely to be severely deﬁ-
cient. It was also possible that CD1a negative DC may have been
present and active within the tumour microenvironment. We
excluded these possibilities by using lin- CD45
+ staining for DC.
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Figure 1 CMRF-44 staining in human breast cancer (Part 1) (6200).
Figure 2 CMRF-56 positive cells in human breast cancer (Part 1)
(6200).
Figure 3 CD1a positive cells in human breast cancer (Part 1) (6200).
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CD83 antibodies were used as another means of detecting DC and
to assess their activation state. These studies showed that few
mature or activated DC could be detected within breast tumours,
implying that DC numbers and activation were indeed absent or
very low in all but one tumour in the 30 tested.
It has been proposed that CD1a acts as a lipid/carbohydrate
carrying glycoprotein, similar in function to major histocompat-
ability complex (MHC) molecules for peptides, with antigen
presentation functions (Hillenbrand, 1994, Hillenbrand et al,
1999; Coventry, 1999). Interestingly, classical MHC molecules
are frequently completely or partially lost from tumour cells with
transition from in-situ to invasive growth (Garrido et al, 1993;
Algarra et al, 2000). CD1a appears to be internalized and/or
downregulated as the DC matures and acquires the ability to
present antigen more efﬁciently. The association between MHC
and CD1a expression in tumours is currently unclear, but this
study appears to exclude major down regulation of CD1a expres-
sion as an additional deﬁcit.
DC are found in low numbers in other tumour types (Troy et al,
1998a,b, 1999) and the density of CD1a positive DC has been
directly correlated with improved overall survival in many solid
tumour types. The ﬁndings of the present study imply that many
breast cancers not only fail to recruit DC but fail to drive DC into
either the antigen capture/processing phase (CD1a
+) or the antigen
presentation/co-stimulatory phase (CMRF-44/56
+). These latter
ﬁndings suggest that the tumour environment may retard or fail
to facilitate maturation/activation of DC. Interleukin 10 has been
shown to exert an inhibitory role over T-lymphocyte reactions
and as such has been suggested as a potential inhibitory molecule
affecting tumour inﬁltrating lymphocytes (TIL) in the breast cancer
microenvironment. Although IL10 showed very low expression it
may exert signiﬁcant inhibition of T-cells in breast carcinoma
(Neville, 1994).
DC migration may contribute to the common pathological ﬁnd-
ing of sinus histiocytosis, producing enlargement of regional,
draining, non-tumour involved lymph nodes in primary breast
(and other) tumours. This is a possible mechanism of induction
of tumour tolerance (Steinbrink et al, 1999). Alternatively, mature
DC may migrate or apoptose and be effectively lost from the
primary tumour microenvironment (Esche et al, 1999; Pirtskha-
laishvili et al, 2000). There is some evidence that anergic T-cells
can induce apoptosis of DC (De Smedt et al, 1998; Vendetti et
al, 2000), and that tumour cells can also cause DC apoptosis
(Kiertscher et al, 2000).
Finally, it is unclear whether re-circulation of tumour anti-
gen-loaded DC occurs back to the primary tumour, and
whether this mechanism of T-cell activation may be defective.
Vascular endothelial growth factor (VEGF) is produced by
tumours to produce neo-vascularization and can function as a
local and systemic inhibitor of DC differentiation, maturation
and function (Gabrilovich et al, 1997, 1998, 1999). Active
suppression of DC function has been previously noted and
was observed to be HLA Class II and CD4 mediated (McLellan
et al, 1999).
TIL isolated from human solid tumours of different types,
including breast carcinoma, have demonstrated poor proliferative
responses to mitogens in-vitro which recovers after several days
co-culture with interleukin-2 (IL-2), or after culture with antigen
presenting cells (APC). In-situ studies of TIL in breast cancers
demonstrate expression of the early activation markers CD38, 43
and 69, but show little or no expression of IL-2 receptor or IL-
2 protein (Coventry et al, 1996), suggesting anergic, tolerant T-
cells. Collectively, these observations suggests that the TIL popula-
tion in breast and other cancers is partially activated, but
effectively rendered anergic. Tumour derived peptides loaded onto
DC have been described to induce T-cell anergy (Grohmann et al,
1997), as one possible mechanism and again the absence of acti-
vated DC is entirely consistent with the possibility that these DC
are providing tolerogenic signals. There is also evidence that aner-
gic T-cells can inhibit antigen presenting functions of DC
(Vendetti et al, 2000). In-vivo reversal of anergy using whole cell,
peptide or membrane-lysate tumour vaccines which can induce
tumour regression in some cases (Hersey, 1993; Soiffer et al,
1998; Haigh et al, 1999; Hart et al, 1999), but the mechanism
remains unclear.
Nevertheless, some signs of activation are present in TIL in
breast cancers which indicates that either T-cells were activated
then became suppressed, or T-cell activation can by-pass the
sparse, poorly activated DC within the tumour microenvironment
to some minor degree. In either case, there is some optimism for
the potential reversal of poor TIL activity and function using a
variety of ex-vivo and in-vivo strategies to activate intra-tumoural
DC, or to provide activated DC capable of effective antigen
presentation to fully activate T-cells within the tumour. Recent
work showing that the DC maturational type and activation
differs between the intra-tumoural and peri-tumoural regions in
a more advanced group of breast cancers supports our ﬁndings
(Bell et al, 1999), and other work indicates DC maturation (and
perhaps activation) can be induced by agents such as prostaglan-
dins (Steinbrink et al, 2000). Taken collectively, these studies
suggest that migration of DC capable of effective activation and
antigen presentation into breast cancers may be defective and stra-
tegies leading to better DC migration may be required also,
irrespective of how many potentially effective DC are delivered
around the tumour.
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Table 1 Fluorescence counts as indicated (Part 2)
Fluorescence counts Per MPF Per mm
2
Case Histology Grade Stage Lin7/45+(F) CD1a Lin7/45+(F) CD1a
1 IDC 2 II 2.5 18 2.9 20.9
2 IDC 3 I 3.4 0.4 3.9 0.5
3 N/D N/D N/D 3.6 0.5 4.2 0.6
4 IDC 3 II 0 0 0 0
5 IDC 1 N/D 8 1 9.3 1.2
6 IDC 2 II 4.6 1.5 5.3 1.7
7 LOB N/D II 5.3 0.13 6.1 0.2
8 N/D N/D N/D 8.5 1.1 9.9 1.3
9 N/D N/D N/D 2 0.25 2.3 0.3
10 Mucinous II 4.6 3.8 5.3 4.4
Means: 4.3 2.7 4.9 3.1
IDC=inﬁltrating ductal carcinoma; LOB=lobular carcinoma; N/D=not deﬁned.
Dendritic cell activation and breast cancer
BJ Coventry et al
549
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 546–551ACKNOWLEDGEMENTS
The authors wish to thank Evy Hillenbrand and Angela Neville
(PhD students) for technical assistance with immunohistochemical
staining, Eric Smith for technical photographic advice, Dr Chris
Atkinson for encouragement and Drs Gill, Carter and Malycha
for providing some of the tissues. Angela Neville supplied the
IL10 work mentioned. Po-Ling Lee was supported in part by a
summer vacation scholarship from the Anti-Cancer Foundation
of the Universities of South Australia. The Health Research Council
and Canterbury Medical Research Foundation also provided some
support (DG; DNJH). The Royal Australasian College of Surgeons
Florance Cancer Research Fellowship Award provided some fund-
ing (BJC). We are grateful for gifts of antibodies from Professors
IFC McKenzie (Melbourne), H Zola (Adelaide), A McMichael
(Oxford). The anti-interleukin 10 (12G8) antibody was kindly
supplied by Schering, NJ, USA.
REFERENCES
Algarra I, Cabrera T, Garrido F (2000) The HLA crossroad in tumor immu-
nology. Hum Immunol 61: 65–73
Ambe K, Mori M, Enjoji M (1989) S-100 protein-positive dendritic cells in
colorectal adenocarcinomas. Distribution and relation to the clinical prog-
nosis. Cancer 63: 496–503
Baxevanis CN, Dedoussis GV, Papodopoulos NG Missitzis I (1994) Tumour
speciﬁc cytolysis by tumour inﬁltrating lymphocytes in breast cancer.
Cancer 74: 1275–1282
Becker Y (1992) Anticancer role of dendritic cells (DC) in human and experi-
mental cancers – a review. Anticancer Res 12: 511–520
Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J,
Davoust J, Palucka KA, Banchereau J (1999) In breast carcinoma tissue,
immature dendritic cells reside within the tumor, whereas mature dendri-
tic cells are located in peritumoral areas. J Exp Med 190: 1417–1426
Coventry BJ, Neoh S, Mantzioris B, Skinner JM, Bradley J, Zola H (1994)
Comparison of the sensitivity of immunoperoxidasestaining methods with
high-sensitivity ﬂuorescence ﬂow cytometry - antibody quantitation on the
cell surface. J Histochem Cytochem 42: 1143–1149
Coventry BJ, Bradley J, Skinner JM (1995) Differences between standard and
high-sensitivity immunoperoxidase staining methods in tissue sections –
Comparison of immunoperoxidase staining methods using computerised
video image analysis. Pathology 27: 221–224
Coventry BJ, Weeks S, Heckford S, Sykes P, Skinner J, Bradley J (1996) Lack
of interleukin-2 (IL-2) cytokine expression despite IL-2mRNA transcrip-
tion in tumour inﬁltrating lymphocytes in primary human breast
carcinoma:selective expression of early activation markers. J Immunol
156: 3486–3492
Coventry BJ, Austyn JM, Chryssidis S, Hankins D, Harris A (1997) Identiﬁca-
tion and isolation of CD1a positive putative tumour inﬁltrating dendritic
cells in human breast cancer. In Dendritic cells in Fundamental and Clinical
Immunology Vol 3: P Ricciardi-Castagnoli (ed) Plenum Press: NY Adv
Exptl Med Biol 417 571–577
Coventry BJ (1999) Review of CD1a putative tumour inﬁltrating dendritic
cells in human breast cancers. AntiCancer Res 19: 3183–3188
De Smedt T, Pajak B, Klaus GG, Noelle RJ, Urbain J, Leo O, Moser M (1998)
Antigen-speciﬁc T lymphocytes regulate lipopolysaccharide-induced apop-
tosis of dendritic cells in vivo. J Immunol 161: 4476–4479
Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC,
Lotze MT, Shurin MR (1999) Tumor’s other immune targets: dendritic
cells. J Leukoc Biol 66: 336–344
Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997)
Decreased antigen presentation by dendritic cells in patients with breast
cancer. Clin Cancer Res 3: 483–490
Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP
(1998) Vascular endothelial growth factor inhibits the development of
dendritic cells and dramatically affects the differentiation of multiple
hematopoietic lineages in vivo. Blood 92: 4150–4166
Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Antibodies to
vascular endothelial growth factor enhance the efﬁcacy of cancer immu-
notherapy by improving endogenous dendritic cell function. Clin Cancer
Res 5: 2963–2970
Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993)
Natural history of HLA expression during tumour development. Immunol
Today 14: 491–499
Grohmann U, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti MC,
Puccetti P (1997) A tumor-associated and self antigen peptide presented by
dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or
revert the anergic state. J Immunol 158: 3593–3602
Hart DN (1997) Dendritic cells: unique leukocyte populations which control
the primary immune response. Blood 90: 3245–3287
Hart DN, Schultze JL, Stewart AK (1999) Presentation of tumor antigens.
Semin Hematol 36(Suppl 3): 21–25
Haigh PI, Difronzo LA, Gammon G, Morton DL (1999) Vaccine therapy for
patients with melanoma. Oncology (Huntingt) 13: 1561–1574
Hersey P (1993) Evaluation of vaccinia viral lysates as therapeutic vaccines in
the treatment of melanoma. Ann NY Acad Sci 690: 167–177
Hillenbrand EE (1994) An immunohistochemical analysis of the distribution
and density of CD1a+ cells in ductal carcinoma of the breast Honours Thesis
University of Adelaide
Hillenbrand EE, Neville AM, Coventry BJ (1999) Immunohistochemical loca-
lisation of CD1a positive putative dendritic cells in human breast tumours.
Br J Cancer 79: 940–944
Hock BD, Starling GC, Hart D (1994) Characterization of CMRF-44, a novel
monoclonal antibody to an activation antigen expressed by allostimulatory
cells within peripheral blood, including dendritic cells. Immunology 83: 573
Hock BD, Fearnley DB, Boyce A, McLellan AD, Sorg RV, Summers KL, Hart
DN (1999) Human dendritic cells express a 95 kDa activation/differentia-
tion antigen deﬁned by CMRF-56. Tis Anti 53: 320–334
Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000) Tumors promote
altered maturation and early apoptosis of monocyte-derived dendritic
cells. J Immunol 164: 1269–1276
McLellan AD, Heiser A, Hart DN (1999) Induction of dendritic cell costimu-
lator molecule expression is suppressed by T cells in the absence of
antigen-speciﬁc signalling: role of cluster formation, CD40 and HLA-class
II for dendritic activation. Immunology 98: 171–180
McLellan AD, Terbeck G, Mengling T, Starling GC, Kiener PA, Gold R,
Brocker EB, Leverkus M, Kampgen E (2000) Differential susceptibility to
CD95 (Apo-1/Fas) and MHC class II-induced apoptosis during murine
dendritic cell development. Cell Death Differ 7: 933–938
Neville AM (1994) Breast Carcinoma – The role of Interleukins 2, 4 and IL10
in human breast cancers, Honours Thesis Adelaide University
Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN,
Lotze MT, Shurin MR (2000) Cytokine-mediated protection of human
dendritic cells from prostate cancer-induced apoptosis is regulated by
the Bcl-2 family of proteins. Br J Cancer 83: 506–513
Schroder S, Schwarz W, Rehpenning W, Loning T, Bocker W (1988) Dendri-
tic/Langerhans cells and prognosis in patients with papillary thyroid
carcinomas. Immunocytochemical study of 106 thyroid neoplasms corre-
lated to follow-up data. Am J Clin Pathol 89: 295–300
Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS,
Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda
R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards
L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G (1998)
Vaccination with irradiated autologous melanoma cells engineered to
secrete human granulocyte-macrophage colony-stimulating factor gener-
ates potent antitumor immunity in patients with metastatic melanoma.
Proc Natl Acad Sci USA 95: 13141–13146
Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH (1999) Inter-
leukin-10-treated human dendritic cells induce a melanoma-antigen-
speciﬁc anergy in CD8(+) T cells resulting in a failure to lyse tumor cells.
Blood 93: 1634–1642
Steinbrink K, Paragnik L, Jonuleit H, Tuting T, Knop J (2000) Induction of
dendritic cell maturation and modulation of dendritic cell-induced
immune responses by prostaglandins. Arch Dermatol Res 292: 437–445
Thomas R, Lipsky E (1996) Could endogenous self-peptides presented by
dendritic cells initiate rheumatoid arthritis?. Immunol Today 12: 559–564
Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN (1998a) Mini-
mal recruitment and activation of dendritic cells within renal cell
carcinoma. Clin Cancer Res 4: 585–593
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Dendritic cell activation and breast cancer
BJ Coventry et al
550
British Journal of Cancer (2002) 86(4), 546–551 ã 2002 Cancer Research UKTroy A, Davidson P, Atkinson C, Hart D (1998b) Phenotypic characterisation
of the dendritic cell inﬁltrate in prostate cancer. J Urol 160: 214–219
Troy AJ, Davidson PJ, Atkinson CH, Hart DN (1999) CD1a dendritic cells
predominate in transitional cell carcinoma of bladder and kidney but are
minimally activated. J Urol 161: 1962–1967
Tsujitani S, Furukawa T, Tamada R, Okamura T, Yasumoto K, Sugimachi K
(1987) Langerhans cells and prognosis in patients with gastric carcinoma.
Cancer 59: 501–505
Tsujitani S, Okamura T, Baba H, Korenaga D, Haraguchi M, Sugimachi K
(1988) Endoscopic intratumoral injection of OK-432 and Langerhans’ cells
in patients with gastric carcinoma. Cancer 61: 1749–1753
Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K (1990)
Inﬁltration of dendritic cells in relation to tumor invasion and lymph node
metastasis in human gastric cancer. Cancer 66: 2012–2016
Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimaghi K
(1992) Inﬁltration of S100 protein positive Dendritic cells and peritoneal
recurrence in advanced gastric cancer. Int Surg 77: 238–241
Vendetti S, Chai JG, Dyson J, Simpson E, Lombardi G, Lechler R (2000)
Anergic T cells inhibit the antigen-presenting function of dendritic cells.
J Immunol 165: 1175–1181
Vuckovic S, Fearnley DB, Mannering SI, Dekker J, Whyte LF, Hart DN (1998)
Generation of CMRF-44+ monocyte-derived dendritic cells: insights into
phenotype and function. Exp Hematol 26: 1255–1264
Zeid NA, Muller HK (1993) S100 positive dendritic cells in human lung
tumors associated with cell differentiation and enhanced survival. Pathol-
ogy 25: 338–343
Zhang XD, Schiller GD, Gill PG, Coventry BJ (1998) Lymphoid cell inﬁltra-
tion during breast cancer growth: A syngeneic rat model. Immunol Cell Biol
76: 550–555
Zhou LJ, Tedder TF (1995) Human blood dendritic cells selectively express
CD83, a member of the immunoglobulin superfamily. J Immunol 154:
3821–3835
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Dendritic cell activation and breast cancer
BJ Coventry et al
551
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 546–551